Otonomy (OTIC): Otipro Setting Up For Sales Inflection - Piper Jaffray
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Piper Jaffray analyst, Joshua Schimmer, reiterated his Overweight rating on shares of Otonomy (NASDAQ: OTIC) now that the launch of OTIC's Otiprio for children undergoing bilateral tympanostomy tube placement (TTP) is underway. Commentary on the company's 2Q earnings call suggests strong progress working with payors and hospital P&T committees to enable access. The analyst expects these efforts to continue throughout the year and to position the company for a sales inflection point around the time of the winter season. There are a number of key data readouts over the next 12-18 months that may meaningfully expand the outlook for the OTIC's franchise. With a modest $240M enterprise value and roughly an equivalent cash position, Otiprio for TTP alone should be able to drive upside over the longer term, and assuming success with any new indication, potential additional and substantive upside awaits.
No change to the price target of $32 which reflects roughly 100% upside.
Shares of Otonomy closed at $17.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Raises Price Target on Microsoft (MSFT) to $65 Following 1Q Beat
- UPDATE: Seaport Global Securities Starts Canadian Pacific Railway Limited (CP) at Buy
- Goldman Sachs Starts Hertz Global (HTZ) at 'Sell' and Avis Budget (CAR) at 'Neutral'
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesPiper Jaffray, Earnings, Joshua Schimmer
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!